30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator?

about

30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator?

Item

http://www.wikidata.org/entity/Q58610127

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

30-day mortality after the sta ...... useful performance indicator?

@en

30-day mortality after the sta ...... useful performance indicator?

@nl

type

Item

label

30-day mortality after the sta ...... useful performance indicator?

@en

30-day mortality after the sta ...... useful performance indicator?

@nl

prefLabel

30-day mortality after the sta ...... useful performance indicator?

@en

30-day mortality after the sta ...... useful performance indicator?

@nl

P1476

30-day mortality after the sta ...... useful performance indicator?

@en

P2093

Jacobus Adrianus Burgers

http://www.w3.org/2001/XMLSchema#string

Ronald Alphons Damhuis

http://www.w3.org/2001/XMLSchema#string

P2860

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Defining a standard set of patient-centred outcomes for lung cancer.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life.

Place of care in advanced cancer: a qualitative systematic literature review of patient preferences.

Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients.

30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.

Chemotherapy remains an essential element of personalized care for persons with lung cancers.

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

P304

00030-2018

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1183/23120541.00030-2018

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30406123

http://www.w3.org/2001/XMLSchema#string

P932

6215912

http://www.w3.org/2001/XMLSchema#string